Renaissance Technologies
TCRX icon

Renaissance Technologies’s TScan Therapeutics TCRX Stock Holding History

Renaissance Technologies’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.3M Sell
1,326,799
-37,984
-3% -$40.5K ﹤0.01% 2190
2026
Q1 		$1.38M Buy
1,364,783
+223,714
+20% +$239K ﹤0.01% 2101
2025
Q4 		$1.14M Buy
1,141,069
+311,150
+37% +$450K ﹤0.01% 2201
2025
Q3 		$1.51M Buy
829,919
+37,863
+5% +$67.1K ﹤0.01% 2251
2025
Q2 		$1.15M Buy
792,056
+622,350
+367% +$899K ﹤0.01% 2434
2025
Q1 		$234K Buy
169,706
+159,106
+1,501% +$344K ﹤0.01% 3027
2024
Q4 		$32.2K Sell
10,600
-63,400
-86% -$287K ﹤0.01% 3444
2024
Q3 		$369K Sell
74,000
-6,000
-8% -$36.2K ﹤0.01% 2902
2024
Q2 		$468K Buy
80,000
+33,000
+70% +$260K ﹤0.01% 2718
2024
Q1 		$373K Buy
47,000
+25,300
+117% +$159K ﹤0.01% 2993
2023
Q4 		$127K Buy
21,700
+4,000
+23% +$18.3K ﹤0.01% 3243
2023
Q3 		$45K Sell
17,700
-129,762
-88% -$303K ﹤0.01% 3421
2023
Q2 		$369K Buy
147,462
+135,862
+1,171% +$364K ﹤0.01% 3032
2023
Q1 		$24K Buy
11,600
+1,600
+16% +$3.8K ﹤0.01% 3796
2022
Q4 		$16K Buy
+10,000
New +$24.5K ﹤0.01% 3996
2022
Q2 		– Sell
-13,300
Closed -$37K – 4567
2022
Q1 		$37K Buy
+13,300
New +$57.5K ﹤0.01% 3948

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $812M AUM 2.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Renaissance Technologies's TCRX Position: Q2 2026 in Review

Renaissance Technologies reduced its TScan Therapeutics (TCRX) stake by 2.8% in Q2 2026, selling an estimated $40.5K and leaving 1,326,799 shares worth $1.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2190.

Renaissance Technologies first reported a position in TCRX in Q1 2022 and has held it in 16 quarters since. The position peaked at $1.51M in Q3 2025. 60 funds tracked by Wall St. Rank hold TCRX as of Q2 2026.

  • Renaissance Technologies held 1,326,799 shares of TScan Therapeutics worth $1.3M as of Q2 2026.
  • Renaissance Technologies sold 37,984 TScan Therapeutics shares in Q2 2026, an estimated $40.5K.
  • TScan Therapeutics made up ﹤0.01% of Renaissance Technologies's portfolio in Q2 2026, its #2190 holding.
  • Renaissance Technologies first reported a position in TScan Therapeutics in Q1 2022 and has held it in 16 quarters since.
  • Renaissance Technologies's TScan Therapeutics position peaked at $1.51M in Q3 2025.
  • 60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.